Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytosorbents (CTSO) Accounts Payables (2016 - 2025)

Cytosorbents' Accounts Payables history spans 15 years, with the latest figure at $2.9 million for Q4 2025.

  • Quarterly results put Accounts Payables at $2.9 million for Q4 2025, down 14.1% from a year ago — trailing twelve months through Dec 2025 was $2.9 million (down 14.1% YoY), and the annual figure for FY2025 was $2.9 million, down 14.1%.
  • Accounts Payables for Q4 2025 was $2.9 million at Cytosorbents, down from $3.0 million in the prior quarter.
  • In the past five years, Accounts Payables ranged from a high of $4.8 million in Q1 2022 to a low of $1.7 million in Q4 2022.
  • The 5-year median for Accounts Payables is $2.9 million (2023), against an average of $2.9 million.
  • Peak annual rise in Accounts Payables hit 187.66% in 2022, while the deepest fall reached 41.0% in 2022.
  • Year by year, Accounts Payables stood at $2.8 million in 2021, then plummeted by 41.0% to $1.7 million in 2022, then soared by 129.71% to $3.8 million in 2023, then decreased by 12.16% to $3.3 million in 2024, then fell by 14.1% to $2.9 million in 2025.
  • According to Business Quant data, Accounts Payables over the past three periods came in at $2.9 million, $3.0 million, and $3.4 million for Q4 2025, Q3 2025, and Q2 2025 respectively.